Brookline Capital Management Comments on MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Monopar Therapeutics in a report issued on Monday, January 6th. Brookline Capital Management analyst K. Dolliver forecasts that the company will post earnings per share of ($0.78) for the quarter. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Brookline Capital Management also issued estimates for Monopar Therapeutics’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($1.27) EPS and FY2025 earnings at ($4.07) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

A number of other brokerages have also recently commented on MNPR. HC Wainwright raised their price target on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Rodman & Renshaw started coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $24.46 on Thursday. The firm has a market cap of $129.10 million, a P/E ratio of -12.42 and a beta of 1.23. The firm’s 50-day simple moving average is $21.62 and its 200-day simple moving average is $10.55. Monopar Therapeutics has a twelve month low of $1.54 and a twelve month high of $38.50.

Insider Buying and Selling

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were bought at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the acquisition, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 34.90% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.